New Variant of Small Cell Lung Cancer Found

A new variant of Small cell Lung cancer has been found in this study. With the discovery of the variant, a gene which is expressed in excess in this particular cancer has also be found.

New variant (kind) of small cell lung cancer has been found in this study. The very the existence of these tuft cells has been proved in this study. The findings of this study are published in the Genes & Development.

"Cancer is not one thing, it's actually hundreds of distinct diseases." This common refrain helps explain the frustrating experience oncologists have in testing a promising new drug only to find that it works well in some patients but fails for the majority. Such experiences have led researchers to believe that the more they can distinguish tumor types based on meaningful biological signatures, the better chance they have of finding subsets of patients that will respond to specific drug candidates.

Twice a Day Radiotherapy Equally Good at Treating Small Cell Lung Cancer
Outcomes for lung cancers have been very poor for a long time, the CONVERT clinical trial is making a real difference in how to treat lung cancer patients.

‘A protein found in the gene regulating variant has also been found which will help serve as a potential target.’

One type of cancer in desperate need of new drug is SCLC, a cancer without a specific treatment that often spreads early. Chemotherapy, radiotherapy, and surgery enable only 6% of patients to survive 5 years from the time of their diagnosis. About 10%-15% of all lung cancers are SCLC.

Fresh insight comes from an analysis of gene activity in human SCLC tumors that is reported today in Genes & Development. It reveals an unexpected activity pattern in around 20% of samples. The research team, led by Christopher Vakoc, M.D., Ph.D., a Cold Spring Harbor Laboratory (CSHL) Associate Professor, found a paucity of neuroendocrine markers in pulmonary neuroendocrine cells, a cell type thought to be the source of SCLC.

To further characterize this minority of cells, Vakoc and colleagues used a method they developed in 2015 that employs the gene-editing tool CRISPR to screen for specific proteins that are critical to the growth of various human cancer cell lines, including SCLC lines. Using this "CRISPR screen," the team found that a transcription factor called POU2F3 is expressed exclusively in the minority of SCLC tumors with low levels of neuroendocrine markers. It turns out that this variant form of SCLC tumors are derived from a separate class of rare cells called tuft cells.

Advanced Stage Non-Small Cell Lung Cancer Patients Have Better Overall Survival
Patients from disparate populations should be evaluated and counseled thoroughly by multidisciplinary teams before choosing to forego treatment for NSCLC.

"We were using the CRISPR screen to discover new vulnerabilities in this disease that we didn't know about before," Vakoc says. "The surprise is that in the process, we discovered a new form of lung cancer."

Developing drugs that specifically target the function of POU2F3 may be particularly effective in the subset of patients with tumors that express high levels of this transcription factor.

Pembrolizumab for Treating Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The advantages of pembrolizumab for non-small cell lung cancer notably outweigh disadvantages in comparison with docetaxel or pemetrexed.

"In the past, we've lumped the different forms of SCLC together because they look similar on a microscope slide, but we now have some molecular tests that can easily discriminate these malignancies," says postdoctoral investigator Yu-Han Huang, first author on the new paper. "Our findings suggest that we should be designing clinical studies for them separately, to find therapies that might cater to the different types of tumor."

Vakoc's team is currently looking for collaborators to do preclinical tests in mice to test compounds that target POU2F3. They also plan to use their CRISPR-based stress test to look for variant types of pancreas cancer which they hope might provide similarly specific targets for treatments.

Researchers Identify New Therapeutic Targets for Small Cell Lung Cancer
Small cell lung cancer is a devastating disease that is diagnosed in 30,000 people a year in the U.S. and accounts for roughly 15 percent of lung cancer cases.

Source-Eurekalert